(HealthDay News) — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those ...

Understanding why we always have room for dessert could lead to new treatments for obesity, researchers have revealed.

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.08. Operator: Good morning, ladies and gentlemen, and welcome to ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

Who hasn't been there? The big meal is over, you're full, but the craving for sweets remains. Researchers have now discovered that what we call the 'dessert stomach' is rooted in the brain. The same ...

Who hasn't been there? The big meal is over, you're full, but the craving for sweets remains. Researchers from the Max Planck ...

In mice, the neurons that dictate the feeling of being full are also the ones that cause sugar cravings, potentially ...

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 PatientsSHIELD II Enrolled more than ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

That is perhaps why there has been so much buzz surrounding the class of drug known as a GLP-1 agonist.

HUNTINGTON — GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza and Wegovy started as a way to treat diabetes but have since become popular tools for weight loss. Dr. Matthew Christiansen ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...